Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer

Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer

Abstract Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TNBC, thus a strategy enabling effective targeted combinations is an unmet need. To tackle th...

Full description

Bibliographic Details
Main Authors: Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M. Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N. Kohale, Judy C. Boughey, Matthew P. Goetz, Liewei Wang, Forest M. White, Nataly Kravchenko-Balasha
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Molecular Cancer
Subjects:
Personalized combined treatment
EGFR
Targeted therapy
Triple-negative breast cancer
Phosphotyrosine proteomics
Information theory
Online Access:https://doi.org/10.1186/s12943-023-01921-9

Internet

https://doi.org/10.1186/s12943-023-01921-9

Similar Items